Price movement over the last 24 hours
Adaptive Biotechnologies Corp vs Pinterest Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Pinterest Inc trades at $22.17 (market cap $12.56B). The key difference: Pinterest Inc is far larger — about 3.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | PINS | |
|---|---|---|
Market Cap | $3.33B | $12.56B |
Sector | Health | Media |
52-Week High | $22.37 | $39.17 |
52-Week Low | $10.24 | $15.42 |
Enterprise Value | $3.19B | $12.47B |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Pinterest (PINS) trades at $22.42, up 1.59% with a bullish technical outlook. The company shows strong revenue growth from $2.8B in 2022 to $4.2B in 2025, though net income margin declined to 7.64% in 2026. Recent AI shopping initiatives and Amazon integration highlight strategic moves to boost monetization. Analyst consensus is bullish with a $27.82 price target, representing 24% upside potential from current levels.
PINS presents a growth opportunity with improving fundamentals and strong analyst support, but faces execution risks in monetizing its user base. The stock's elevated P/E ratio of 46.35 requires sustained earnings growth to justify valuation. Competitive pressures in social media and dependency on advertising revenue remain key challenges for long-term investors.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →